Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer

Journal of Urology

Volumn 194, Issue 2, 2015, Pages 547-555

  Li, David R ^a   Zhang, Hanwei ^a   Peek, Elizabeth ^a   Wang, Song ^c   Du, Lin ^a   Li, Gang ^a,b   Chin, Arnold I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

apoptosis; chromatin; cisplatin; histone deacetylase inhibitors; urinary bladder neoplasms

Indexed keywords

AR 42; CISPLATIN; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE; OSU-HDAC42 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; DRUG EFFICACY; DRUG POTENTIATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; CELL PROLIFERATION; DRUG EFFECTS; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PHENYLBUTYRATES; URINARY BLADDER NEOPLASMS;

EID: 84952631516     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.02.2918     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11
2. H. Von der Maase, S.W. Hansen, J.T. Roberts, and et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068
3. R.M. Drayton, and J.W.F. Catto Molecular mechanisms of cisplatin resistance in bladder cancer Expert Rev Anticancer Ther 12 2012 271
4. O. Witt, H.E. Deubzer, T. Milde, and et al. HDAC family: what are the cancer relevant targets? Cancer Lett 277 2009 8
5. S. Shankar, and R.K. Srivastava Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis Adv Exp Med Biol 615 2008 261
6. H.M. Prince, and M. Dickinson Romidepsin for cutaneous T-cell lymphoma Clin Cancer Res 18 2012 3509
7. D. Siegel, M. Hussein, C. Belani, and et al. Vorinostat in solid and hematologic malignancies J Hematol Oncol 2 2009 31
8. C. Poyet, B. Jentsch, T. Hermanns, and et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer BMC Clin Pathol 14 2014 10
9. Cancer Genome Atlas Research Network Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315
10. M.T. Buckley, J. Yoon, H. Yee, and et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo J Transl Med 5 2007 49
11. S. Vallo, W. Xi, L. Hudak, and et al. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro Anticancer Drugs 22 2011 1002
12. W. Qu, Y.D. Kang, M.S. Zhou, and et al. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells Urol Oncol 28 2010 648
13. A. Ozawa, N. Tanji, T. Kikugawa, and et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor BJU Int 105 2010 1181
14. M.L. Guzman, N. Yang, K.K. Sharma, and et al. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia Mol Cancer Ther 13 2014 1979
15. S. Sharma, J. Symanowski, B. Wong, and et al. A phase II clinical trial of oral valproic acid in patients with castration-resistant prostate cancers using an intensive biomarker sampling strategy Transl Oncol 1 2008 141
16. E.M. Peek, D.R. Li, H. Zhang, and et al. Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model Am J Cancer Res 2 2012 745
17. Y. Zhang, Z. Wang, J. Yu, and et al. Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer Cancer Lett 322 2012 70
18. K.S. Chan, I. Espinosa, M. Chao, and et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells Proc Natl Acad Sci U S A 106 2009 14016
19. W. Choi, S. Porten, S. Kim, and et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy Cancer Cell 25 2014 152
20. T. Powles, J.P. Eder, G.D. Fine, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558
21. D. Wang, Y. Jing, S. Ouyang, and et al. Inhibitory effect of valproic acid on bladder cancer in combination with chemotherapeutic agents in vitro and in vivo Oncol Lett 6 2013 1492
22. S.K. Kulp, C.S. Chen, D.S. Wang, and et al. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer Clin Cancer Res 12 2006 5199
23. J.-P. Volkmer, D. Sahoo, R.K. Chin, and et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes Proc Natl Acad Sci U S A 109 2012 2078
24. S. Jamaladdin, R.D.W. Kelly, L. O'Regan, and et al. Histone deacetylase (HDAC) 1 and 2 are essential for accurate cell division and the pluripotency of embryonic stem cells Proc Natl Acad Sci U S A 111 2014 9840
25. B. Del Bello, M. Toscano, D. Moretti, and et al. Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells PLoS One 8 2013 e57236
26. T. Robert, F. Vanoli, I. Chiolo, and et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy Nature 471 2011 74